Author Archives: abcuro

Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis  Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle … Read More

Clinical leader brings deep expertise in clinical development, medical and regulatory affairs Newton, MA, June 2, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells today … Read More

Financing round led by Mass General Brigham Ventures and Sanofi Ventures Proceeds to support advancement of the lead autoimmune program into clinical development, as well as further development of the company’s pipeline  Newton, MA, January 7, 2021– Abcuro, Inc., a … Read More

Inclusion body myositis (IBM)is an autoimmune condition in which cytotoxic T cells chronically attack muscle cells, leading to progressive weakness and severe disability Abcuro’s lead program, ABC008, is an anti-KLRG1 antibody capable of depleting highly differentiated cytotoxic T cells that … Read More

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in inclusion body myositis (IBM), titled “Highly Differentiated Cytotoxic T Cells in Inclusion Body Myositis”. IBM is an autoimmune disease characterized by T cell infiltration and attack … Read More

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in primary biliary cholangitis (PBC), titled “Cytotoxic KLRG1 Expressing Lymphocytes Invade Portal Tracts in Primary Biliary Cholangitis”. PBC is an autoimmune disease characterized by T cell … Read More

Abcuro Inc., announced that it has been awarded a Small Business Innovation Research Grant (SBIR) from the NIH National Cancer Institute. This Phase I grant will support advancement of the company’s anti-KLRG1 blocking antibody (ABC-015) with support for testing in … Read More

Berlin, Germany, May 23rd, 2019 ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, … Read More

Antibody blockade induces anticancer response in solid tumor models. First in vivo validation of KLRG1 as a cancer immunotherapy target. KLRG1 is a driver of adaptive resistance to immunotherapy in humans. NEWTON, Mass., March 26, 2019 /PRNewswire/ — Abcuro, Inc., a biopharmaceutical … Read More